NFKB1 and congenital rubella syndrome: Finally, TLRs have NF-κB as a downstream target, and NF-κB inhibition (e.g., by direct inhibitors or proteasome inhibitors [39]), should therefore be considered as a possible therapeutic strategy in CRS.